Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) is now available.
GenFleet Therapeutics (Shanghai) Inc. has called an extraordinary general meeting for 9 February 2026 in Shanghai, where shareholders will vote on a series of measures aimed at refining its equity incentive framework, capital management and governance structure. The agenda includes proposed adoption of an H Share Option Scheme and an H Share Incentive Scheme, the setting of overall scheme and service-provider sublimits, and authorization for the board to manage these plans, as well as a mandate allowing the company to repurchase up to 10% of its issued H shares and amendments to its Articles of Association that include abolishing the Supervisory Committee, steps that collectively signal a move toward greater capital flexibility, enhanced talent incentives and a streamlined corporate governance model for investors and other stakeholders.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong, operating in the biopharmaceutical sector. The company focuses on the research, development and commercialization of innovative therapeutic products, serving both domestic and international healthcare markets through its H-share listing on the Hong Kong Stock Exchange.
Average Trading Volume: 740,241
For an in-depth examination of 2595 stock, go to TipRanks’ Overview page.